Misonix to Present at the 43rd Annual Deutsche Bank Health Care Conference on May 8

FARMINGDALE, N.Y., April 23, 2018 -- Misonix, Inc. (NASDAQ:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Deutsche Bank 43^rd Annual Health Care Conference held at the Intercontinental Hotel in Boston, Massachusetts on Tuesday, May 8, 2018. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation at 1:30 p.m. ET that day followed by a question and answer session. 

Mr. Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be available to meet with institutional investors in one-on-one meetings throughout the day.

The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at [email protected].

About Misonix, Inc.
Misonix, Inc. (NASDAQ:MSON) designs, develops, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix's proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s 59-year history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.